BRMS1L

Across TCGA pan-cancer cohorts, BRMS1L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BRMS1L data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BRMS1L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BRMS1L expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where BRMS1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.889	0.510	<.001	51	view →
UCEC	DFS	Quartile	II,III,IV	0.380	1.000	.006	24	view →
LSCC	DFS	Tertile	II,III,IV	0.884	0.461	.006	9	view →
HNSC	DFS	Quartile	All	1.000	0.881	.012	6	view →
LUAD	OS	Quartile	III,IV	0.702	0.298	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BRMS1L–CCRCC (DFS)

Open the CCRCC breakdown →